2025年3月4日周二，Lantheus Holdings Inc（纳斯达克股票代码：LNTH）在TD Cowen第45届年度医疗保健会议上发表演讲，概述了公司在放射性药物领域提升患者治疗效果的战略重点。公司强调了其雄心勃勃的增长计划，包括潜在的收购和新产品上市，同时也认识到竞争压力和市场动态。

根据SEC文件显示，市值68.9亿美元的医疗诊断公司Lantheus Holdings, Inc.（NASDAQ:LNTH）董事Mary Anne ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

(Lantheus or the Company ... the agreements to acquire Life Molecular and Evergreen Theragnostics. Both acquisitions are expected to close in the second half of 2025, subject to customary ...

Lantheus aims to close acquisitions of Life Molecular Imaging and Evergreen Theranostics to bolster growth. The company plans to launch new assets, including MK 6,240, NAV 4,694, Octavie ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...